Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India's Biocon Issues One-For-One Bonus Shares, Says Acquisitions, New Drug Development To Drive Earnings

This article was originally published in PharmAsia News

Executive Summary

BANGALORE, India - India's largest biotechnology drug firm Biocon said clinical trials for diabetes, psorasis, arthritis and cancer drugs are progressing and it plans to launch a new cardio-diabetes division to focus on brand building for its statin Statix (atorvastatin)

You may also be interested in...



India’s Biocon Buys 70 Percent Stake In German Drug Firm AxiCorp GmbH

BANGALORE, India - India's Biocon Ltd. said it paid €30 million ($43.5 million) to buy a 70 percent stake in German drug firm AxiCorp GmbH to expand marketing and distribution of products such as injectable insulin, generics, biosimilars and biologics in Europe

Biocon Partners With Biotech Startup In Latest India-U.S. Deal

NEW DELHI - Biocon, India's largest biotechnology company, said it would list its Syngene research service unit next financial year and make a "strategic" investment in U.S. firm IATRICa to co-develop a new class of immunoconjugates that provides targeted immunotherapy for cancers and infectious diseases

Abraxis Licenses Rights To Biosimilar From Indian Firm Biocon

Abraxis BioScience and Biocon have signed a licensing agreement that gives the Los Angeles firm the right to develop a biosimilar of granulocyte-colony stimulating factor in North America and the European Union, the companies announced July 19

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel